{
    "Clinical Trial ID": "NCT00006110",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Herceptin Regimen After AC",
        "  Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).",
        "INTERVENTION 2: ",
        "  Herceptin Regimen After TP",
        "  Patients in the adjuvant and neoadjuvant groups after receiving chemotherapy and Taxol + Herceptin."
    ],
    "Eligibility": [
        "Inclusion Criteria",
        "  Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast",
        "  Fine needle aspiration, core needle biopsy, or incisional biopsy allowed",
        "  No excisional biopsy",
        "  Any of the following:",
        "  Tumor size 2, Nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0)",
        "  Any T with N2 (including axillary lymph nodes matted to one another) or N3",
        "  Any T4, including inflammatory breast cancer",
        "  Adjuvant patients with at least 4 positive lymph nodes and HER-2 overexpressing tumor",
        "  Supraclavicular or infraclavicular positive lymph nodes without distant metastases",
        "  Distant metastases with measurable disease in breast or lymph nodes",
        "  Synchronous bilateral primary breast cancer allowed if the more serious cancer meets entry criteria",
        "  Measurable or evaluable disease",
        "  PATIENT CHARACTERISTICS:",
        "  Age: Not specified",
        "  Sex: Female",
        "  Menopausal status: Not specified",
        "Performance status: Not specified",
        "  Life expectancy: Not specified",
        "  Hematopoietic:",
        "  White cell count > 3000 / mm3 Platelet count > 100,000 / mm3",
        "  Hemoglobin > 9 mg / dl Bilirubin < 1.5 x normal Creatinine < 1.5 x normal left ventricular ejection fraction (LVEF) normal by resting nuclear ventriculogram Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception",
        "  Exclusions",
        "  Prior malignancies except:",
        "  Effectively treated squamous cell or basal cell skin cancer Carcinoma in situ of the cervix that has been curatively treated by surgery alone Nonbreast malignancy from which patient has been disease-free for 5 years and is at low risk of recurrence"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC.",
        "  Doxorubicin + cyclophosphamide in combination with paclitaxel and trastuzumab (AC-TP) Associated Systolic Dysfunction. Systolic function was measured by the ventricular ejection fraction (LVEF). LVEF is a measurement in determining how well your heart is pumping out blood and in diagnosing and tracking heart failure.",
        "  Time frame: 78 weeks (1.5 years)",
        "Results 1: ",
        "  Arm/Group Title: Herceptin Regimen After AC",
        "  Arm/Group Description: Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).",
        "  Overall Number of Participants Analyzed: 52",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Asymptomatic LVEF < 50%: 1   1.9%",
        "  Congestive Heart Failure: 0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: Herceptin Regimen After TP",
        "  Arm/Group Description: Patients in the adjuvant and neoadjuvant groups after receiving chemotherapy and Taxol + Herceptin.",
        "  Overall Number of Participants Analyzed: 50",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Asymptomatic LVEF < 50%: 8  16.0%",
        "  Congestive Heart Failure: 1   2.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 7/52 (13.46%)",
        "  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)",
        "  Atrial Fibrillation * 1/52 (1.92%)",
        "  Sepsis * 1/52 (1.92%)",
        "  Muscle weakness upper limb * 1/52 (1.92%)",
        "  Dizziness * 1/52 (1.92%)",
        "  Seizure * 1/52 (1.92%)",
        "  Nervous system disorders - Other, specify *  [1]1/52 (1.92%)",
        "Adverse Events 2:",
        "  Total: 1/30 (3.33%)",
        "  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)",
        "  Atrial Fibrillation * 0/30 (0.00%)",
        "  Sepsis * 0/30 (0.00%)",
        "  Muscle weakness upper limb * 0/30 (0.00%)",
        "  Dizziness * 0/30 (0.00%)",
        "  Seizure * 0/30 (0.00%)",
        "  Nervous system disorders - Other, specify *  [1]0/30 (0.00%)"
    ]
}